EGFR and central nervous system cancer: The present study aimed to investigate the anti-tumor efficacy of AZD3759 against glioma and determine its underlying mechanism to provide more clinical evidence for the application of AZD3759 for the treatment of patients with glioma and EGFR-sensitive mutations in clinical settings.